AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

by Barry101 | Sep 5, 2023 | Press Release

OCALA, Fla., Sept. 05, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment...

AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements

by Barry101 | Aug 23, 2023 | Press Release

Group Seeking to Take Control of 75% of AIM Board Failed to Properly Disclose Myriad Interconnections, Understandings and Arrangements Among Its Members – Violating the Company’s Bylaws and Preventing Shareholders from Being Able to Make Fully Informed...

AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update

by Barry101 | Aug 15, 2023 | Press Release

– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and webcast today at 8:30 AM ET OCALA, Fla., Aug. 15, 2023 — AIM...

AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

by Barry101 | Aug 9, 2023 | Press Release

OCALA, Fla., Aug. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q2 2023 operational and financial...

AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

by Barry101 | Aug 8, 2023 | Press Release

Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a potential...